Western blot analysis of Colo 205 cells treated (+) with combinations of the following treatments as indicated: hydrogen peroxide (500 μM, 5 min), hydrogen peroxide-treated lysates treated with phosphodiesterase 1 (0.5 μg/mL, 4 hr at 37ºC), or with tcPARG (5 μM, 4 hr at 37ºC ) using Poly/Mono-ADP Ribose (E6F6A) Rabbit mAb (upper), or GAPDH (D16H11) XP® Rabbit mAb #5174 (lower).
Western blot analysis of Colo 205 cells untreated (-), or treated with hydrogen peroxide (500 μM, 5 min; +), using Poly/Mono-ADP Ribose (E6F6A) Rabbit mAb (upper), or β-Tubulin (9F3) Rabbit mAb #2128 (lower).
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
From sample preparation to detection, the reagents you need for your Western Blot are now in one convenient kit: #12957 Western Blotting Application Solutions Kit
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised June 2020
Protocol Id: 10
Poly/Mono-ADP Ribose (E6F6A) RmAb recognizes endogenous levels of ADP ribosylated proteins and does not cross-react with other post translational modifications.
All Species Expected
Monoclonal antibody is produced by immunizing animals with KLH modified on lysines with ADP ribose.
ADP-ribosylation is a post-translational modification that has been described to occur on the side chain of several acceptor residues (lysine, arginine, glutamate, aspartate, cysteine, serine) and protein amino termini as well as on DNA and tRNA (1). ADP-ribosyl transferases (ADPRTs) catalyze the transfer of ADP-ribose from β-NAD+ and release nicotinamide in the process. Mono-ADP-ribosyl transferases (MARTs, or monoPARPs) comprise the vast majority of the ADPRTs. These monoenzymes, which include the sirtuins and many of the PARP (ARTD) and ART proteins, transfer a single ADP-ribose unit to the target residue (MARylation). The poly-ADP-ribose polymerases (polyPARPs) or polyenzymes, which include human PARP1, 2, 5a and 5b, are the most widely studied and can polymerize linear or branched chains of up to ~200 ADPR units (2). Specificity is determined primarily, but not exclusively, by a nonconsecutive catalytic triad motif, with some exceptions. Those containing the R-S-E motif like Cholera toxin are arginine-directed transferases, while those containing the H-Y-E triad tend to exhibit polymerase activity (3,4). ADP-ribosylation is reversible and can be degraded down to a single ADP-ribose unit by poly-ADP-ribose glycohydrolase (PARG) or ADP-ribosylhydrolase 3 (ARH3) or completely removed from the target residue by ARH1, TARG1, MacroD1 or MacroD2 (5).
ADP-ribosylation is involved in a variety of cellular processes, including mitotic spindle formation, chromatin decondensation, cell stress response, retroviral silencing, RNA biology, and transcription, but the most well-known function of ADP-ribose chains is to serve as a scaffold for recruiting DNA repair proteins that contain PAR-binding modules to sites of DNA damage (6). X-ray repair cross-complementing protein 1 (XRCC1), histone macroH2A1, RNF146 (Iduna) an E3 ubiquitin ligase, and many of the PARPs themselves, among others, contain PAR-binding motifs (PBMs) or domains: WWE, PAR-binding zinc-finger (PBZ), or macrodomains (7). PARylation has a central role in cell survival, and is tightly regulated. PARP deficiency can leave a cell vulnerable to DNA damage-induced apoptosis, while hyper PARylation can lead to parthanatos, a unique form of cell death (8). The role of PARylation in DNA repair has inspired great interest in developing candidate drug inhibitors for PARP, in particular to treat breast, prostate and small cell lung cancers with mutations in DNA repair genes like BRCA1/2, CHK2 or ATM. Stat1, PERK, p53, G-actin and Ras are just a few examples of proteins that are functionally modulated by ADP-ribosylation (6,7). Modification by ADP-ribose can block protein interactions or, in the case of P2X7, cause a conformational change that in the presence of ART2 expression sensitizes naive murine T-cells to extracellular NAD+ leading to apoptosis (9).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.